CSNK1A1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL60528	0.51	9/20
SCHEMBL61733	0.51	9/20
SCHEMBL61527	0.52	8/20
SCHEMBL60391	0.51	8/20
SCHEMBL61354	0.49	8/20
SCHEMBL69434	0.49	8/20
Hydrochloric Acid (SCHEMBL61915)	0.48	8/20
SCHEMBL68145	0.52	7/20
SCHEMBL60743	0.52	7/20
SCHEMBL61185	0.52	7/20
Hydrochloric Acid (SCHEMBL61070)	0.51	7/20
SCHEMBL62227	0.51	7/20
SCHEMBL60831	0.59	6/20
SCHEMBL61307	0.59	6/20
SCHEMBL61273	0.52	6/20
SCHEMBL60859	0.45	6/20
SCHEMBL69095	0.67	5/20
SCHEMBL67376	0.64	5/20
SCHEMBL66923	0.60	5/20
SCHEMBL67192	0.60	5/20

Clinical trials — most relevant to CSNK1A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Cardiac REperfusion With Intralipid® at Reperfusion	PHASE2/PHASE3	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor	PHASE2	RECRUITING
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma	PHASE1	UNKNOWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	nan	COMPLETED
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Family Blood Pressure Program - HyperGEN	nan	COMPLETED
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization	nan	COMPLETED
Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease	nan	COMPLETED
IPSC Repository of Pediatric Cardiovascular Disease	nan	RECRUITING
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)	nan	COMPLETED
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD)	nan	UNKNOWN
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Study of a Candidate Gene Involved in Goldenhar Syndrome.	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CSNK1A1 binder may also engage these)

Protein	Name	Similarity
P67962	—	1.000	P67962 →
P67963	—	1.000	P67963 →
Q8BK63	—	1.000	Q8BK63 →
P97633	—	1.000	P97633 →
P67828	—	1.000	P67828 →
P67829	—	1.000	P67829 →
P67827	—	0.999	P67827 →
CSNK1A1L	Casein kinase I isoform alpha-like	0.995	landscape →
P42168	—	0.990	P42168 →
G5EI58	—	0.989	G5EI58 →
A0A0E0S0W9	—	0.986	A0A0E0S0W9 →
P40235	—	0.983	P40235 →
B9VVJ6	—	0.983	B9VVJ6 →
Q7T2E3	—	0.983	Q7T2E3 →
Q6QNM1	—	0.981	Q6QNM1 →
P54367	—	0.978	P54367 →
Q5BP74	—	0.978	Q5BP74 →
Q6P647	—	0.978	Q6P647 →
Q9DC28	—	0.977	Q9DC28 →
Q5RC72	—	0.977	Q5RC72 →
Q06486	—	0.976	Q06486 →
Q4R9A9	—	0.975	Q4R9A9 →
Q6QNL9	—	0.974	Q6QNL9 →
Q6P3K7	—	0.973	Q6P3K7 →
CSNK1E	Casein kinase I isoform epsilon	0.973	landscape →
Q5ZLL1	—	0.972	Q5ZLL1 →
Q62761	—	0.971	Q62761 →
CSNK1D	Casein kinase I isoform delta	0.971	landscape →
P35508	—	0.971	P35508 →
Q9JMK2	—	0.968	Q9JMK2 →